XNAS
HSIC
Market cap9.55bUSD
Jul 09, Last price
83.86USD
1D
0.77%
1Q
11.31%
Jan 2017
40.96%
Name
Henry Schein Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, governmental entities, and various institutional and alternative healthcare facilities. Its operations are organized into two principal segments: Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution division supplies an extensive array of dental goods, encompassing consumables (such as infection control items, impression materials, composites, anesthetics, and artificial teeth), specialized tools and equipment (like handpieces, dental chairs, delivery units, X-ray machinery, and advanced digital restoration systems), and personal protective equipment. This segment also provides essential equipment repair services. Furthermore, it distributes a broad range of medical supplies, including pharmaceuticals (both branded and generic), vaccines, surgical instruments, diagnostic kits, infection prevention solutions, imaging products, equipment, and nutritional supplements. The Technology and Value-Added Services segment focuses on empowering practices with advanced software, technology, and supplementary solutions. This includes specialized practice management software systems tailored for both dental and medical professionals. Beyond software, it delivers crucial value-added practice support services, such as non-recourse financial assistance, electronic services, comprehensive technology and network infrastructure support, hardware services, ongoing professional development programs, and expert consulting. Established in 1932, Henry Schein, Inc. maintains its corporate headquarters in Melville, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2021‑12 | 2020‑12 | 2020‑12 | 2019‑12 | 2019‑12 | 2018‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||||||
Revenues | |||||||||||||||
Cost of revenue | |||||||||||||||
Unusual Expense (Income) | |||||||||||||||
NOPBT | |||||||||||||||
NOPBT Margin | |||||||||||||||
Operating Taxes | |||||||||||||||
Tax Rate | |||||||||||||||
NOPAT | |||||||||||||||
Net income | |||||||||||||||
Dividends | |||||||||||||||
Dividend yield | |||||||||||||||
Proceeds from repurchase of equity | |||||||||||||||
BB yield | |||||||||||||||
| Debt | |||||||||||||||
Debt current | |||||||||||||||
Long-term debt | |||||||||||||||
Deferred revenue | |||||||||||||||
Other long-term liabilities | |||||||||||||||
Net debt | |||||||||||||||
| Cash flow | |||||||||||||||
Cash from operating activities | |||||||||||||||
CAPEX | |||||||||||||||
Cash from investing activities | |||||||||||||||
Cash from financing activities | |||||||||||||||
FCF | |||||||||||||||
| Balance | |||||||||||||||
Cash | |||||||||||||||
Long term investments | |||||||||||||||
Excess cash | |||||||||||||||
Stockholders' equity | |||||||||||||||
Invested Capital | |||||||||||||||
ROIC | |||||||||||||||
ROCE | |||||||||||||||
| EV | |||||||||||||||
Common stock shares outstanding | |||||||||||||||
Price | |||||||||||||||
Market cap | |||||||||||||||
EV | |||||||||||||||
EBITDA | |||||||||||||||
EV/EBITDA | |||||||||||||||
Interest | |||||||||||||||
Interest/NOPBT | |||||||||||||||